BACKGROUND: What characterizes individuals whose natural killer (NK) cells are able to respond to HIV-1 peptides is not known. METHODS: The association between NK cell responses and KIR gene profiles and HLA-B and HLA-C alleles was investigated among 76 HIV-1-infected women in South Africa previously categorized as responders (n = 39) or nonresponders (n = 37) to HIV-1 peptide pools in a whole blood intracellular cytokine assay. Viral load was significantly lower and CD4 T-cell counts higher among responders compared with nonresponders (P = 0.023 and P = 0.030, respectively). RESULTS: Possession of one HLA-C1 allele associated with increased magnitude of NK cell responses to Env (P = 0.031) and significantly decreased viral load (P = 0.027) compared with its absence. There was a trend to increased possession of KIR2DL3+HLA-C1 in responders (71.8% vs 51.4%, P = 0.098) and decreased possession of KIR2DL3/2DL3+C2C2 (2.6% vs 16.2%, P = 0.053). A total of 64.1% of responders versus 32.4% of nonresponders had 13 or more KIR genes (P = 0.0067). Notably, the 13-KIR gene containing the Bx21 genotype (has eight inhibitory and three activating genes KIR2DS2, 2DS4, 2DS5) showed substantially higher representation among the responders (28.2% vs 2.6%, P = 0.001). A significantly higher proportion of responders had both KIR2DS2 and KIR2DS5 compared with either gene alone (72.4% vs 37%; P = 0.015). At least one HLA-C1 allele together with 13 or more KIR genes was associated with NK cell responsiveness (48.7% vs 13.5%; P = 0.001). CONCLUSION: NK cell responses to HIV-1 peptides are more likely to occur among individuals with a genotype supporting a more activating NK cell phenotype and who possess at least one HLA-C1 allele.
BACKGROUND: What characterizes individuals whose natural killer (NK) cells are able to respond to HIV-1 peptides is not known. METHODS: The association between NK cell responses and KIR gene profiles and HLA-B and HLA-C alleles was investigated among 76 HIV-1-infectedwomen in South Africa previously categorized as responders (n = 39) or nonresponders (n = 37) to HIV-1 peptide pools in a whole blood intracellular cytokine assay. Viral load was significantly lower and CD4 T-cell counts higher among responders compared with nonresponders (P = 0.023 and P = 0.030, respectively). RESULTS: Possession of one HLA-C1 allele associated with increased magnitude of NK cell responses to Env (P = 0.031) and significantly decreased viral load (P = 0.027) compared with its absence. There was a trend to increased possession of KIR2DL3+HLA-C1 in responders (71.8% vs 51.4%, P = 0.098) and decreased possession of KIR2DL3/2DL3+C2C2 (2.6% vs 16.2%, P = 0.053). A total of 64.1% of responders versus 32.4% of nonresponders had 13 or more KIR genes (P = 0.0067). Notably, the 13-KIR gene containing the Bx21 genotype (has eight inhibitory and three activating genes KIR2DS2, 2DS4, 2DS5) showed substantially higher representation among the responders (28.2% vs 2.6%, P = 0.001). A significantly higher proportion of responders had both KIR2DS2 and KIR2DS5 compared with either gene alone (72.4% vs 37%; P = 0.015). At least one HLA-C1 allele together with 13 or more KIR genes was associated with NK cell responsiveness (48.7% vs 13.5%; P = 0.001). CONCLUSION: NK cell responses to HIV-1 peptides are more likely to occur among individuals with a genotype supporting a more activating NK cell phenotype and who possess at least one HLA-C1 allele.
Authors: M C Sirianni; F Ensoli; C Alario; V Fiorelli; G Sacco; S Topino; F Iebba; I Mezzaroma; F Aiuti Journal: Hum Immunol Date: 2001-12 Impact factor: 2.850
Authors: S Gaudieri; D DeSantis; E McKinnon; C Moore; D Nolan; C S Witt; S A Mallal; F T Christiansen Journal: Genes Immun Date: 2005-12 Impact factor: 2.676
Authors: Manuela Fogli; Paola Costa; Giuseppe Murdaca; Maurizio Setti; Maria Cristina Mingari; Lorenzo Moretta; Alessandro Moretta; Andrea De Maria Journal: Eur J Immunol Date: 2004-08 Impact factor: 5.532
Authors: Maureen P Martin; Xiaojiang Gao; Jeong-Hee Lee; George W Nelson; Roger Detels; James J Goedert; Susan Buchbinder; Keith Hoots; David Vlahov; John Trowsdale; Michael Wilson; Stephen J O'Brien; Mary Carrington Journal: Nat Genet Date: 2002-07-22 Impact factor: 38.330
Authors: Domenico Mavilio; Janet Benjamin; Marybeth Daucher; Gabriella Lombardo; Shyam Kottilil; Marie A Planta; Emanuela Marcenaro; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta; Anthony S Fauci Journal: Proc Natl Acad Sci U S A Date: 2003-11-25 Impact factor: 11.205
Authors: Louise E Hogan; Christian Körner; Kristen Hobbs; Camille R Simoneau; Cassandra Thanh; Erica A Gibson; Christine D Palmer; Alisha Pandit; Francisco M Marty; Daniel R Kuritzkes; Stephanie Jost; Jerome Ritz; Timothy J Henrich Journal: Blood Adv Date: 2018-06-26
Authors: Daniela Garrido-Rodríguez; Santiago Ávila-Ríos; Claudia García-Morales; Humberto Valenzuela-Ponce; Christopher Ormsby; Helena Reyes-Gopar; Juan Carlos Fernandez-Lopez; Gustavo Reyes-Terán Journal: Immunogenetics Date: 2016-05-30 Impact factor: 2.846
Authors: Christina F Thobakgale; Lena Fadda; Kimberly Lane; Ildiko Toth; Florencia Pereyra; Suzane Bazner; Thumbi Ndung'u; Bruce D Walker; Eric S Rosenberg; Galit Alter; Mary Carrington; Todd M Allen; Marcus Altfeld Journal: J Virol Date: 2012-04-11 Impact factor: 5.103
Authors: Katarzyna Zwolińska; Olga Błachowicz; Tomasz Tomczyk; Brygida Knysz; Jacek Gąsiorowski; Małgorzata Zalewska; Beata U Orzechowska; Marta Sochocka; Egbert Piasecki Journal: Immunogenetics Date: 2016-02-18 Impact factor: 2.846